VTYX logo

Ventyx Biosciences (VTYX) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

21 October 2021

Indexes:

Not included

Description:

Ventyx Biosciences is a biotechnology company focused on developing innovative treatments for autoimmune and inflammatory diseases. They aim to create new therapies that improve patients' lives by targeting specific biological pathways. Their research combines advanced science with a commitment to addressing unmet medical needs.

Events Calendar

Earnings

Next earnings date:

Feb 27, 2025

Recent quarterly earnings:

Nov 07, 2024

Recent annual earnings:

Feb 27, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

11 Nov '24 HC Wainwright & Co.
Neutral
08 Nov '24 Oppenheimer
Outperform
15 Oct '24 HC Wainwright & Co.
Neutral
23 Sept '24 HC Wainwright & Co.
Neutral
12 Aug '24 Wells Fargo
Overweight
12 Aug '24 Canaccord Genuity
Buy
30 July '24 HC Wainwright & Co.
Neutral
13 June '24 HC Wainwright & Co.
Neutral
06 June '24 Oppenheimer
Outperform
06 June '24 HC Wainwright & Co.
Neutral

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
VTYX
globenewswire.com12 November 2024

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease
VTYX
globenewswire.com06 September 2024

SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson's disease.

Ventyx Biosciences Announces Departure of Chief Financial Officer
Ventyx Biosciences Announces Departure of Chief Financial Officer
Ventyx Biosciences Announces Departure of Chief Financial Officer
VTYX
globenewswire.com30 August 2024

SAN DIEGO, Aug. 30, 2024 (GLOBE NEWSWIRE) --  Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Martin Auster, M.D. has departed from his role as Chief Financial Officer, effective August 30, 2024. Roy Gonzales, CPA, MBA, the Company's SVP of Finance, has assumed the roles of interim Principal Financial Officer and interim Principal Accounting Officer for SEC reporting purposes. The company has initiated a search for a CFO.

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
VTYX
globenewswire.com28 August 2024

SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress
Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress
Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress
VTYX
globenewswire.com08 August 2024

A Phase 2 obesity and cardiometabolic trial of VTX3232 and a Phase 2a trial of VTX3232 in patients with Parkinson's disease are both expected to initiate in H2 2024

VENTYX SHAREHOLDER ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Notified to Contact the Firm for Details
VENTYX SHAREHOLDER ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Notified to Contact the Firm for Details
VENTYX SHAREHOLDER ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Notified to Contact the Firm for Details
VTYX
accesswire.com25 June 2024

NEW YORK, NY / ACCESSWIRE / June 25, 2024 / Top law firm Bleichmar Fonti & Auld LLP is investigating Ventyx Biosciences's (Nasdaq:VTYX) Board for Insider Trading. If you are a shareholder of Ventyx, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation.

VENTYX STOCK ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Encouraged to Contact the Firm for Details
VENTYX STOCK ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Encouraged to Contact the Firm for Details
VENTYX STOCK ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Encouraged to Contact the Firm for Details
VTYX
globenewswire.com25 June 2024

NEW YORK, June 25, 2024 (GLOBE NEWSWIRE) -- Top law firm Bleichmar Fonti & Auld LLP is investigating Ventyx Biosciences's (Nasdaq:VTYX) Board for Insider Trading. If you are a shareholder of Ventyx, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation.

VENTYX INVESTOR UPDATE: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Urged to Contact the Firm for Details
VENTYX INVESTOR UPDATE: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Urged to Contact the Firm for Details
VENTYX INVESTOR UPDATE: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Urged to Contact the Firm for Details
VTYX
accesswire.com24 June 2024

NEW YORK, NY / ACCESSWIRE / June 24, 2024 / Top law firm Bleichmar Fonti & Auld LLP is investigating Ventyx Biosciences's (Nasdaq:VTYX) Board for Insider Trading. If you are a shareholder of Ventyx, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation.

VENTYX INVESTOR ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Encouraged to Contact the Firm for Details
VENTYX INVESTOR ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Encouraged to Contact the Firm for Details
VENTYX INVESTOR ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Encouraged to Contact the Firm for Details
VTYX
globenewswire.com22 June 2024

NEW YORK, June 22, 2024 (GLOBE NEWSWIRE) -- Top law firm Bleichmar Fonti & Auld LLP is investigating Ventyx Biosciences's (Nasdaq:VTYX) Board for Insider Trading. If you are a shareholder of Ventyx, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation.

VENTYX INVESTOR NOTICE: Ventyx's (NASDAQ:VTYX) Board is Being Investigated for Insider Trading Allegations, Long-term Investors Are Urged to Contact the Firm for Details
VENTYX INVESTOR NOTICE: Ventyx's (NASDAQ:VTYX) Board is Being Investigated for Insider Trading Allegations, Long-term Investors Are Urged to Contact the Firm for Details
VENTYX INVESTOR NOTICE: Ventyx's (NASDAQ:VTYX) Board is Being Investigated for Insider Trading Allegations, Long-term Investors Are Urged to Contact the Firm for Details
VTYX
accesswire.com21 June 2024

NEW YORK, NY / ACCESSWIRE / June 21, 2024 / Top law firm Bleichmar Fonti & Auld LLP is investigating Ventyx Biosciences's (NASDAQ:VTYX) Board for Insider Trading. If you are a shareholder of Ventyx, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation.

FAQ

  • What is the primary business of Ventyx Biosciences?
  • What is the ticker symbol for Ventyx Biosciences?
  • Does Ventyx Biosciences pay dividends?
  • What sector is Ventyx Biosciences in?
  • What industry is Ventyx Biosciences in?
  • What country is Ventyx Biosciences based in?
  • When did Ventyx Biosciences go public?
  • Is Ventyx Biosciences in the S&P 500?
  • Is Ventyx Biosciences in the NASDAQ 100?
  • Is Ventyx Biosciences in the Dow Jones?
  • When was Ventyx Biosciences's last earnings report?
  • When does Ventyx Biosciences report earnings?
  • Should I buy Ventyx Biosciences stock now?

What is the primary business of Ventyx Biosciences?

Ventyx Biosciences is a biotechnology company focused on developing innovative treatments for autoimmune and inflammatory diseases. They aim to create new therapies that improve patients' lives by targeting specific biological pathways. Their research combines advanced science with a commitment to addressing unmet medical needs.

What is the ticker symbol for Ventyx Biosciences?

The ticker symbol for Ventyx Biosciences is NASDAQ:VTYX

Does Ventyx Biosciences pay dividends?

No, Ventyx Biosciences does not pay dividends

What sector is Ventyx Biosciences in?

Ventyx Biosciences is in the Healthcare sector

What industry is Ventyx Biosciences in?

Ventyx Biosciences is in the Biotechnology industry

What country is Ventyx Biosciences based in?

Ventyx Biosciences is headquartered in United States

When did Ventyx Biosciences go public?

Ventyx Biosciences's initial public offering (IPO) was on 21 October 2021

Is Ventyx Biosciences in the S&P 500?

No, Ventyx Biosciences is not included in the S&P 500 index

Is Ventyx Biosciences in the NASDAQ 100?

No, Ventyx Biosciences is not included in the NASDAQ 100 index

Is Ventyx Biosciences in the Dow Jones?

No, Ventyx Biosciences is not included in the Dow Jones index

When was Ventyx Biosciences's last earnings report?

Ventyx Biosciences's most recent earnings report was on 7 November 2024

When does Ventyx Biosciences report earnings?

The next expected earnings date for Ventyx Biosciences is 27 February 2025

Should I buy Ventyx Biosciences stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions